No Data
Cloud Top Nova-B (01952) recently continuously released heavy research data and made key progress, the domestic market is expected to enter a period of outbreak.
Recently, Hong Kong-listed innovative drug company YunDing XinYao-B (01952) released a blockbuster product - the world's first IgA nephropathy targeted therapy drug Nefecon (budesonide enteric capsules) NefIgArd Phase III clinical trial global open-label extension (OLE) study, announcing positive data at the American Society of Nephrology (ASN) Kidney Week 2024.
The Yunding Xin Yao announces the positive results of the extension study of the second treatment course of Phase III trial of Nephacan, providing new evidence for long-term treatment strategy for IgA nephropathy.
Genting Bio-Pharma (HKEX 1952.HK) is a biopharmaceutical company focused on the research and development, clinical development, manufacturing, and commercialization of innovative drugs, today announced the results of the open-label extension (OLE) study of the global Phase III clinical trial NefIgArd of Nefcourant (budesonide enteric capsules, NEFECON) will be presented at the 2024 American Society of Nephrology (ASN).
This week, Hong Kong stocks' star stocks | Expectations of top brokerages merging are hyped! A-share trading is hot! China-affiliated brokerage stocks collectively soaring; shanghai electric group skyrocketed by 62% in one week, officially announcing merg
This week, the Hong Kong stock market ended four consecutive weeks of decline, with daily levels still fluctuating. The Hang Seng Index rose by 1.08% to 20,728.19 points; during the same period, the Hang Seng Tech Index rose by 4.11% to 4,668.26 points; the Hang Seng China Enterprises Index rose by 1.62% to 7,461.44 points.
Hong Kong stock market retreats from its high levels, with the Hang Seng Index and the H-share Index both falling by over 1%; the real estate and brokerage sectors decline, Sunac drops more than 9%, Citic Securities falls by nearly 6%.
Network technology stocks decline, NetEase-S drops by 5.61%, Meituan-W drops by 4.05%; Securities and brokerage stocks weaken, CSC drops by 5.45%, China International Capital Corporation drops by 4.34%; Coal industrial concept stocks weaken, China Coal Energy drops by 4.22%, Kinetic Dev drops by 3.18%.
Bocom Intl: The tenth batch of national procurement starts with reported volumes. Bullish on sector sentiment improvement + valuation recovery after medical insurance negotiations land.
bocom intl highly recommends akeso (09926), simcere pharma (02096), legend biotech (LEGN.US), silver crest new yaobin-B (01952), and hutchmed (china) (00013), etc.
HK Stock Market Update | Genting Hong Kong -B (01952) surged more than 8% in the afternoon. National medical insurance negotiations have ended, institutions bullish on innovative varieties being included in medical insurance for increased trading volume.
Genting New Star-B (01952) rose more than 8% in the afternoon, as of the time of publication, up 6.94% to HK$33.15, with a turnover of 0.195 billion Hong Kong dollars.
No Data
No Data